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The influence of assay method on single dose cyclo-
sporine (CsA) pharmacokinetics was studied in nine dogs 
receiving either i.v. or oral CsA. Samples were drawn 
from hepatic, portal, and systemic veins at various times 
after the dose and CsA levels were determined by radi-
oimmunoassay (RIA) and high-performance liquid chro-
matography (HPLC). Blood concentration-time data 
were analyzed by nonlinear least-squares regression, 
using two-compartment models. RIA/HPLC ratios for 
all samples were greater than one, and did not change 
significantly over time. The mean RIA/HPLC ratios for 
samples drawn from all three veins were higher after 
oral than i.v. doses of the drug (P<0.05). Area under 
the concentration-time curve (AUC) was higher and sys-
temic clearance (CIs) lower than calculated on the basis 
of RIA results, regardless of the route of administration. 
AUC calculated for CsA metabolites (RIA-HPLC) was 
highest in the portal vein after an oral dose of CsA. 
Bioavailability was 20.4% and 27.0% when estimated 
using HPLC and RIA data, respectively. The mean CsA 
metabolite index (CMI) , when calculated for hepatic, 
portal, or systemic vein, was greater when the drug was 
administered orally. The mean hepatic extraction ratio 
(HER) of the parent drug and for CsA metabolites was 
approximately 23 % in i. v. and p.o. studies. These results 
suggest that the gastrointestinal tract may play a role 
in the metabolism of CsA when the drug is administered 
orally. In addition, if CsA metabolites not measured by 
HPLC have either toxic or immunosuppressive proper-
ties, the RIA assay may be more useful for monitoring 
patients. 
The introduction of cyclosporine (CsA)& in the immunosup-
pressive regimen has proven to be the single most important 
component of success in organ transplantation over the last 
few years. The drug does not exhibit the bone marrow toxic 
side effects of immunosuppressive agents used previously, and 
it exerts selective and reversible inhibition of stimulated T 
lymphocyte proliferation, apparently by blocking the produc-
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tion of interleukin-2 (1). These advantages are partially offset 
by the several toxic side effects that have been encountered 
with increased clinical use of CsA (2, 3). Furthermore, it is 
often difficult to maintain stable therapeutic blood levels of the 
drug. Thus, there is considerable interest in the pharmacoki-
netics and metabolism of CsA (4-7). 
Two techniques are available to determine blood, plasma, 
and serum levels of the drug: the radioimmunoassay (RIA) 
technique detects the parent drug plus some of the metabolites, 
and the high performance liquid chromatography (HPLC) tech-
nique detects the parent drug only. As might be expected, CsA 
blood levels determined with the RIA technique are consistently 
higher than the corresponding values determined by HPLC. 
The objective of the present study was to understand the 
significance of the difference between HPLC and RIA meas-
urements of the drug, particularly as it relates to the pharma-
cokinetics of CsA. The results of the study suggest that there 
is significant metabolism of the drug by the gastrointestinal 
tract when administered orally. 
MATERIALS AND METHODS 
Experimental procedures. Adult mongrel dogs (weighing 18-
22 kg) were used in these studies. The animals were anesthe-
tized and intubated, and the portal vein, a hepatic vein (through 
the right external jugular vein), and a peripheral vein were 
cannulated The dogs were allowed to recover from the surgery 
for 24-48 hr. On the morning of the study, after an overnight 
fast, a venous blood sample for baseline CsA levels was with-
drawn. The animals were then given an Lv. bolus (5 mgfkg) or 
an oral p.o. dose (17.5 mg/kg) of CsA (these are the daily 
dosages of CsA used clinically by the authors). The oral dose 
was administered slowly with a syringe, directly into the dog's 
mouth. No other drugs were given either before or during CsA 
administration. Then 2 ml of blood was collected in heparinized 
tubes for CsA blood level determination from each Lv. line at 
the following times after administration of the drug: 10 and 20 
min (onl¥ for Lv. studies), 0.5, 1, 2, 4, 6, 8, and 24 hr. The 
samples were stored immediately at -20·C until further proc-
essing. Five Lv. and five p.o. studies were conducted. 
Cyclosporine assay. CsA concentration was determined by 
HPLC, using a modification of the method of Sawchuk and 
Cartier (8). The column temperature was maintained at 70·C. 
Flow rate of the mobile phase, acetonitrile/methanol/distilled 
water (49/22/29 by volume) was 1.0 ml/min. Column effluent 
was monitored at 214 nm. Peak heights were measured man-
ually, and the ratio of CsA to the internal standard cyclosporin 
D was used to calculate drug concentration. CsA concentration 
was measured by RIA according to the Sandoz kit instructions. 
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Data analysis. CsA concentration-time data were fitted with 
DRUGFUN, a nonlinear least-squares regression program 
available on the PROPHET system (9). All CsA concentration 
data were weighted as the reciprocal of the measured value 
squared (l/y2). Pharmacokinetic parameters were then calcu-
lated by fitting the data to two-compartment models, BOLUS 
2 for the i.v. data, and KA2 for the p.o. data, which assumes a 
first-order absorption of the drug. This analysis provides esti-
mates of the volume of distribution of the central compartment 
(Vd); the initial (tl/za) and terminal (tl/2m half-lives; the distri-
bution rate constant from tissues to blood (K21); systemic 
clearance (CIs); lagtime from ingestion to oral absorption; and 
area under the concentration-time curve (AUC). Bioavailability 
was calculated by equation 1: 
o/c b· ·1 bT - (dose i.v.)(AUC p.o.) x 00 
o lOaval a 1 lty - (d )(AUC.) 1 ose p.o. l.V. (1) 
To estimate the concentration of CsA metabolites, the dif-
ference between RIA and HPLC drug levels was calculated. 
This quantity represents an underestimation of metabolite 
concentration because crossreactivity of the metabolites with 
the RIA antibody is variable. An index of CsA metabolite 
production was calculated using equation 2: 
CsA metabolite index (CM!) 
AUC RIA - AUC HPLC 
= AUC RIA x 100 (2) 
The hepatic extraction ratio (HER) of the parent drug was 
calculated using the AUC values derived from portal (AUCpv) 
and hepatic (AUCbv) venous blood samples: 
HER = AUCpv - AUChv 
AUCpv 
(3) 
In this equation, only HPLC determinations were used. The 
AUC of CsA metabolites (AUC-MET) was calculated by sub-
tracting the AUC derived from the HPLC measurements from 
the AUC derived from RIA measurements of CsA blood levels. 
The HER of the CsA metabolites (HER· MET) was calculated 
by the equation: 
HER.MET = AUC.METpv - AUD·METhv 
AUC.METpv 
(4) 
where AUC·METpv and AUC·METbv were the AUC·MET in 
the portal and hepatic vein blood, respectively. The paired t 
test was used for comparison of RIA/HPLC ratios, calculated 
pharmacokinetic parameters, and CM!. 
RESULTS 
CsA blood levels were consistently higher by RIA than HPLC 
(Figs. 1, 2). Consequently, the RIA/HPLC ratios were always 
greater than one. These ratios did not change significantly over 
the time ofthe i.v. studies. Furthermore, the mean RIA/HPLC 
ratios were significantly higher after p.o. than i.v. administra-
tion of the drug (Table 1). These differences were apparent in 
systemic, portal, and hepatic blood. 
The RIA and HPLC concentration-time data from i.v. and 
p.o. studies were fitted to two-compartment models (Tables 2 
and 3). Several.differences were observed in the pharamcoki-
netic parameters. In both the i.v. and p.o. studies, the AUC by 
HPLC was significantly lower than the AUC by RIA. The CIs 
6.0 
5.0 
E 4.0 
..... 
0' 
:l, 
..., 3.0 
<t 
"' U 
...... 2.0 
1.0 
0 2 4 6 8 
TIME (hr.) 
FIGURE 1. Mean hepatic vein CsA blood concentration after i.v. 
administration of 5 mg/kg CsA. Each point is the mean of CsA 
determinations in five animals, with bars indicating standard error. 
(--0--) RIA determinations (-_e--) HPLC determination. 
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FIGURE 2. Mean hepatic vein CsA blood concentration was deter-
mined at various times after p.o. administration of 17.5 mg/kg CsA. 
Bars indicate standard error of the mean of four values (--0--) 
RIA determination; (--e--) HPLC determination. 
in the i. v. studies based on HPLC blood levels were higher than 
those based on RIA. Bioavailability in four experiments, cal-
culated on the basis of the HPLC data, was 20.4% (range 9.6-
30.S) and 27.0% (range 21.9-32.6) when estimated using RIA 
CsA blood levels. 
The mean CMI in systemic blood were 36% and 54% for CsA 
i.v. and p.o. administration studies, respectively (P<0.05). Sim-
ilarly, in portal and hepatic blood, the CMI was higher after 
p.o. than i.v. administration of the drug (Table 4). The highest 
mean A UC· MET was observed in the portal vein after oral 
administration of CsA. 
The mean HER of the parent drug were 23% and 25% in the 
i.v. and p.o. studies, respectively. Total hepatic blood flow in 
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TABLE 1. RIA/HPLC ratios of blood CsA concentration after a 
single i.v. or p.o. dose of the drug 
. i.v. 
p.o. 
Systemic 
vein 
1.48 
2.12 
Portal 
vein 
1.51 
2.06 
Hepatic 
vein 
1.73 
2.13 
TABLE 2. Pharmacokinetic parameters after a single i.v. dose of CsA 
(samples drawn from a systemic vein, CsA concentration determined 
using RIA and HPLC) 
Vd t'f, tlh Cis (mil Aue (,.g. 
(l/kg) (hr) (hr) min/kg) minim\) 
HPLC: x 1.65 0.91 8.54 7.06 859 
SE 0.15 0.09 0.73 0.87 151 
RIA: x 1.48 0.01 16.2 4.40 1315 
SE 0.28 0.004 6.7 0.43 137 
TABLE 3. Pharmacokinetic parameters after a single p.o. dose of CsA 
(samples drawn from a systemic vein; CsA concentration determined 
using RIA and HPLC) 
Lagtime t'h Aue (,.g. 
(hr) (hr) minim\) 
HPLC: it 0.54 6.84 752 
SE 0.14 1.11 104 
RIA: x 0.29 9.05 1697 
SE 1.11 1.11 283 
TABLE 4. AUC·MET and eM! after an Lv. or p.o. dose ofCsA 
(blood samples obtained from hepatic, portal, and systemic veins at 
various times after the dose) 
Lv. 
p.o. 
Systemic vein Portal vein Hepatic vein 
AUC·MET eM! (%) Aue·MET CM! (%) Aue·MET CM! (%) 
452 
945 
36 
54 
459 
1124 
41 
56 
463 
868 
43 
53 
conscious dogs has been estimated at about 30.9 ml/min/kg 
(10). Using this value and the calculated HER, a mean hepatic 
clearance of 7.11 ml/min/kg after i.v. administration of CsA 
may be calculated. This value is virtually identical to the mean 
CIs of 7.06 ml/min/kg obtained using the pharmacokinetic 
parameters based on the systemic blood samples (Table 2). The 
calculated HER for the CsA metabolites were 22% after i.v. 
and 23% after p.o. administration of the drug. 
DISCUSSION 
The pharmacokinetic analysis of CsA concentration-time 
data show that in both i.v. and p.o. studies the AUC is higher 
and CIs lower when calculated on the basis of RIA CsA blood 
concentration. The clinical relevance of this difference is not 
obvious. Yee et al. (7) suggest that differences in CIs measure-
ments resulting from different assay techniques can signifi-
cantly affect dosage recommendations. However, targeted CsA 
levels are different depending on whether RIA or HPLC is used 
to monitor CsA therapy. In this study, for example, the mean 
CIs calculated on the basis of HPLC was 7.06 ml/min/kg; if 
the selected average CsA target blood concentration at steady 
state is 400 ng/'~l \" HPLC, then the required CsA i.v. dose, 
calculated as target concentration times clearance, would be 
4.1 mg/kg/24 hr. Since the RIA/HPLC ratio observed in this 
study was 1.5, the equivalent RIA-targeted CsA average blood· 
concentration would be 600 ng/ml. The required dose of CsA 
to maintain this blood concentration, calculated using the CIs 
derived from RIA studies (4.40 ml/min/kg), would be 3.8mg/ 
kg/24 hr. It is suggested, therefore, that either HPLC-derived 
or RIA-derived pharmacokinetic parameters may be used to 
estimate CsA intravenous dosages, as long as the optimal target 
CsA blood level has been determined by the same technique as 
the one used to make dosage recommendations. However, RIA 
measures both parent drug and metabolites, which introduces 
additional variability, so extra caution should be used when 
calculating pharmacokinetic parameters using RIA data. For 
example, the average tlI2/J after an i.v. dose appears to be twofold 
higher when calculated using RIA than by HPLC (Table 2), 
but the standard error for the RIA value is so large that the 
difference between the RIA and HPLC tl/2P values is not 
statistically significant. 
For the oral drug, the required dose is calculated as target 
concentration times clearance divided by bioavailability. Using 
a target concentration of 400 ng/ml and the HPLC pharmaco-
kinetic data, the required dose would be 19.9 mg/kg/24 hr. For 
RIA monitoring of an oral dose, the target should be 2.1 times 
the HPLC target, because the average RIA/HPLC ratio for a 
p.o. dose is 2.1 (Table 2). Using a target value of 840 ng/ml 
(2.1x400) and the RIA bioavailability, the calculated dose is 
19.7 mg/kg/24 hr, virtually identical to the dose suggested by 
HPLC pharmacokinetics. 
We suggest that either RIA or HPLC pharmacokinetics can 
be used to calculate dose requirements with quite similar re-
sults, provided that appropriate target values are used and that 
the RIA/HPLC ratio is known for the particular situation. To 
achieve the desired concentrations of parent, immunosuppres-
sive drug, the RIA target in healthy dogs must be 1.5 times the 
HPLC target for i.v. administration of the drug, and 2.1 times 
for p.o. This suggested difference in target RIA values for Lv. 
versus p.o. drug administration appears to be a new observation 
which may have clinical utility. The reason that a higher RIA 
target is needed for oral drug is the presence of a larger quantity 
of metabolites when drug is given p.o. 
The clinical usefulness of RIA pharmacokinetics as a tool to 
achieve desired levels of parent CsA depends on the interpatient 
and intrapatient variability in the RIA/HPLC ratio, as well as 
the size of the acceptable range of parent CsA levels. Especially 
if metabolites not measured by HPLC have either toxic or 
immunosuppressive properties, the RIA determination may be 
particularly helpful. Regardless of which assay method is being 
used, CsA blood levels must continue to be monitored periodi-
cally throughout the time the patient is receiving the drug. 
In this work, the difference between RIA and HPLC CsA 
concentrations was used as a tool to explore the patterns of 
CsA metabolism after i.v. and p.o. administration of the drug. 
It appears that a greater quantity of metabolites is present in 
the blood when CsA is given orally; the RIA/HPLC ratios were 
significantly higher in the p.o. than in the i.v. studies. Further-
more, in the p.O. studies, the A UC· MET was highest in the 
portal vein, suggesting that after oral administration of CsA, a 
part of the drug is metabolized by the gastrointestinal flora and 
mucosa. The resulting metabolites and the absorbed parent 
drug are carried to the liver by the portal blood. From the 
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calculated HER of the parent drug and metabolites, it appears 
that CsA and its metabolites are eliminated by the liver at an 
almost equal rate whether the drug is administered i.v. or orally. 
The larger quantity of metabolites detected in the systemic and 
hepatic blood after oral CsA administration seems to be of 
gastrointestinal origin. When the drug is given orally, the 
additional metabolites of gut origin cannot be immediately 
excreted by the liver and are delivered to systemic circulation. 
These metabolites are responsible for the higher RIA/HPLC 
ratios described in the p.o. studies. 
As already reported, CsA appears to be a low-to-intermediate 
extraction drug (11), the clearance of which is therefore more 
dependent on hepatic intrinsic clearance than on liver blood 
flow. The most frequently reported CsA bioavailability ranges 
from 20 to 50% (12, 13). As a consequence, the oral dosages 
required to attain the same esA blood levels as after i.v. 
administration should be 2-5 times the i.v. CsA dose. If the 
orally administered, absorbed drug was metabolized only by the 
liver, it might be expected that the amount of metabolites 
delivered to the systemic circulation would be of the same order 
of magnitude as after i.v. administration of esA. These metab-
olites would be those produced in the liver and not immediately 
excreted in the bile. The finding that maximal amounts of esA 
metabolites are present in the portal vein after oral adminis-
tration of the drug suggests that, as the liver extracts metabo-
lites and the parent drug at a fixed rate, the CsA metabolites 
of gastrointestinal origin are partially delivered to the hepatic 
and systemic blood. Further studies must be conducted to 
elucidate the mechanism by which these metabolites are gen-
erated. 
It is therefore apparent that bioavailability calculations ob-
tained from RIA esA blood concentration data might be un-
predictably affected by the presence of the additional metabo-
lites of gut origin. It is well recognized that alterations in liver 
function can affect esA pharmacokinetics (14); however, when 
esA is given orally, even alterations in the flora and the 
enzymatic activity of the mucosa of the gastrointestinal tract 
may significantly affect esA metabolism and pharmacokinetics. 
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